Table 1.
List of pharmacological drugs commonly used in vascular response investigation.
| Class | Reagents | Reagents' full description |
|---|---|---|
| Nonspecific AR agonist | NECA | 5′-N-Ethylcarboxamidoadenosine |
|
| ||
| Specific A2AAR agonist | CGS 21680 | 2-p-(2-Carboxyethyl)phenethylamino-5′-N-ethylcarboxamidoadenosine hydrochloride hydrate |
|
| ||
| A2AAR antagonist | ZM241385 | 4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol |
| SCH-58261 | 7-(2-Phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine | |
|
| ||
| A1AR agonist | CCPA | 2-Chloro-N6-cyclopentyladenosine |
|
| ||
| A1AR antagonist | DPCPX | 8-Cyclopentyl-1,3-dipropylxanthine |
|
| ||
| eNOSi | L-NAME | N-Nitroarginine methyl ester |
|
| ||
| CYP-epoxygenases inhibitor | MS PPOH | N-(Methylsulfonyl)-2-(2-propynyloxy)-benzenehexanamide |
|
| ||
| CYP-hydroxylase | DDMS | Dibromododecenyl methylsulfimide |
|
| ||
| Cyclooxygenase inhibitor | Indomethacin | |
|
| ||
| sEH inhibitors | AUDA | 12-(3-adamantan-1-yl-ureido)-dodecanoic acid |
| t-AUCB | trans-4-[4-(3-Adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid | |
|
| ||
| EET antagonist | 14,15-EEZE | 14,15-Epoxyeicosa-5(z)-enoic acid |
|
| ||
| 20-HETE inhibitor | HET0016 | N-Hydroxy-N′-(4-n-butyl-2-methylphenyl)formamidine |
|
| ||
| KATP channel blocker | Glibenclamide | |
|
| ||
| Mitochondrial-KATP channel blocker | 5-HD | 5-Hydroxydecanoate |
|
| ||
| PPARγ agonist | Rosiglitazone | |
|
| ||
| PPARα antagonist | GW 6471 | N-((2S)-2-(((1Z)-1-Methyl-3-oxo-3-(4-(trifluoromethyl)phenyl)prop-1-enyl)amino)-3-(4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy)phenyl)propyl)propanamide |